CoChat

Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

Foltynie, Thomas, Aviles-Olmos, Iciar · 2014 · Alzheimer's & Dementia
Cited by 49

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: There is an increasing number of approaches to try and relieve the motor symptoms of Parkinson's disease (PD) that focus predominantly on strategies of dopaminergic replacement or deep brain stimulation. There remains, however, a major need to slow down or reverse the relentless progression of the disease to prevent the evolution of disabling motor and nonmotor features that continue to cause disability despite the existing symptomatic approaches. Data emerging from the laboratory suggest that agonists for the glucagonlike peptide 1 (GLP‐1) receptor may have biological properties relevant to PD pathogenesis and progression. Methods: Future progress in the evaluation of GLP‐1 agonists such as exenatide as potential disease‐modifying treatments in PD can be facilitated by collection of proof‐of‐concept data to mitigate against the risk associated with major financial investments into these agents. There are, nevertheless, multiple issues that must be considered in the planning, setup, and conduct of pilot trials of potential disease‐modifying drugs. Results: Open‐label proof‐of‐concept data have been collected in a small cohort of patients with moderate severity PD that suggest that this agent is well tolerated. Patients randomized to receive exenatide showed advantages on validated motor and nonmotor scales of PD that persisted after a 2‐month drug washout period. Conclusions: Although data must be interpreted with caution, given the strong possibility of placebo effects, the clinical evaluation of these patients supports additional investment into double‐blind trials of the GLP‐1 agonists in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.12.005

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 49

Metadata

Authors
Foltynie, T., & Aviles-Olmos, I.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-02
Volume
10
Issue
1S
Pages
S38-46
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2069884615
Cited by
49
References
16
FWCI
3.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic. https://app.cochat.ai/papers/10.1016/j.jalz.2013.12.005
The paper
Foltynie, T., & Aviles-Olmos, I. (2014). Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.12.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.